Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers
Authors:
Open Access
- 1 February 1993
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 37 (2) , 265-269
Abstract
Some macrolide antibiotics cause clinical drug interactions, resulting in altered metabolism of concomitantly administered drugs, via formation of an inactive cytochrome P-450 complex. In the present study, the formation of a cytochrome P-450 type I binding spectrum and a metabolic intermediate complex by troleandomycin and dirithromycin was assessed in liver microsomes obtained from untreated rats and phenobarbital- or dexamethasone-pretreated rats. Troleandomycin produced a type I binding spectrum and metabolic intermediate complex in microsomes from dexamethasone- and phenobarbital-pretreated rats. Dirithromycin did not produce a detectable type I binding spectrum but formed a small cytochrome P-450 metabolic intermediate complex (6% of that formed by troleandomycin) in microsomes from dexamethasone-pretreated rats only. The formation of a cytochrome P-450 type I binding spectrum and a metabolic intermediate complex by troleandomycin, erythromycin, dirithromycin, and erythromycylamine was also assessed in microsomes prepared from human livers. Troleandomycin and erythromycin formed a type I binding spectrum and a metabolic intermediate complex which were larger in microsomes from subjects on barbiturate therapy than in microsomes from subjects with no recent barbiturate exposure. Erythromycylamine did not form a detectable type I binding spectrum with any of the human microsomal samples, but a small metabolic intermediate complex was formed with microsomes from a subject on phenobarbital, phenytoin, and propranolol therapy. Dirithromycin did not form a detectable type I binding spectrum or a metabolic intermediate complex in any human liver sample. Preclinical quantitation of the human metabolic intermediate complex may be helpful in predicting the possibility of clinical drug interactions of new drug candidates.Keywords
This publication has 16 references indexed in Scilit:
- The Human Hepatic Cytochromes P450 Involved in Drug MetabolismCritical Reviews in Toxicology, 1992
- Formation of reactive intermediates and metabolites: Effects of macrolide antibiotics on cytochrome P-450Pharmacology & Therapeutics, 1987
- Identification of an inducible form of cytochrome P-450 in human liver.Proceedings of the National Academy of Sciences, 1985
- Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450pBiochemistry, 1985
- Pharmacokinetic Interactions of the Macrolide AntibioticsClinical Pharmacokinetics, 1985
- Dual effects of macrolide antibiotics on rat liver cytochrome P-450Biochemical Pharmacology, 1983
- Effects of erythromycin on hepatic drug-metabolizing enzymes in humansBiochemical Pharmacology, 1983
- Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humansBiochemical Pharmacology, 1982
- Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agentsXenobiotica, 1982
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951